Hence the use of a non-toxic anti-Gal-3 agent in conjunction with a toxic chemotherapeutic drug may be a useful therapeutic strategy for chemoresistant prostate cancers [9]. This evidence concerns the gene LGALS3 and prostate carcinoma.